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Cellular resistance mechanisms are a major obstacle to the
successful treatment of disseminated malignancies using
chemotherapeutic agents. Studies of cell lines made resistant to
natural product agents indicate that ATP-binding cassette (ABC)
transporters represent important resistance mechanisms associated
with these agents. The paradigm for this resistance mechanism is
P-glycoprotein (P-gp), which functions as a plasma membrane
efflux pump to reduce intracellular levels of natural product cyto-
toxic agents (Gottesman and Pastan, 1993). More recently, organic
anion transporters have been implicated as efflux pumps that
confer resistance to natural product cytotoxic agents. The
multidrug resistance-associated transporter (MRP), an ABC trans-
porter that shares limited amino acid identity with P-gp (Cole et al,
1992), has been shown to confer a resistance phenotype that over-
laps with that of P-gp (Cole et al, 1994; Grant et al, 1994; Kruh et
al, 1994; Zaman et al, 1994; Breuninger et al, 1995). In contrast to
P-gp, which transports lipophilic amphipathic compounds, MRP
functions as an efflux pump for amphipathic anionic conjugates,
including glutathione-S conjugates and glucuronidated and
sulphated compounds (Leier et al, 1994; Muller et al, 1994;
Jedlitschky et al, 1996; Loe et al, 1996). Increasing evidence
suggests that an organic anion transporter closely related to MRP,
the canalicular multispecific organic acid transporter (cMOAT)
(Buchler et al, 1996; Paulusma et al, 1996; Taniguchi et al, 1996),
also plays a role in cytotoxic drug resistance. Although the resis-
tance phenotype of cMOAT has not yet been established in trans-
fection studies, cMOAT has been reported to be overexpressed in
cell lines selected for resistance to cisplatin (Taniguchi et al, 1996;
Kool et al, 1997), and transfection of a cMOAT antisense vector
was reported to sensitize a liver cancer cell line to cytotoxic drugs
(Koike et al, 1997). In addition, cMOAT-transfected cells have
been reported to exhibit enhanced efflux of the natural product
drug vincristine (Evers et al, 1998), and a cMOAT-deficient rat
strain has been reported to have decreased excretion of
methotrexate into the bile (Masuda et al, 1997). Together these
studies concerning MRP and cMOAT indicate that organic anion
transporters are important in cellular resistance to cytotoxic drugs
and possibly the excretion of some of these agents into the bile.
The participation of organic anion transporters in cellular resis-
tance and in the hepatobiliary excretion of cytotoxic drugs
suggested that other MRP/cMOAT-related pumps might be rele-
vant to the drug treatment of cancer and analyses in our laboratory
(MG Belinsky and GD Kruh, unpublished data) and others
(Allikmets et al, 1996; Kool et al, 1997) of expressed sequence tag
databases suggested that related human transporters exist. Using a
variety of experimental approaches, we previously isolated the
full-length coding sequences of three MRP/cMOAT-related trans-
porters, designated MOAT-B, MOAT-C and MOAT-D (Belinsky
et al, 1998; Lee et al, 1998). These three transporters correspond to
previously reported EST sequences designated MRP4, MRP5 and
MRP3 (Allikmets et al, 1996; Kool et al, 1997), respectfully, and
in the case of MOAT-C, the partial peptide SMRP (Suzuki et al,
1997). The possibility that an additional MRP/cMOAT subfamily
member might exist was suggested by a recent report describing
ARA, a cDNA isolated from an anthracycline-resistant cell line
and encoding a predicted 453 residue peptide (Longhurst et al,
1996). However, our analysis of the reported ARA cDNA indi-
cated that it represents a fused transcript that encodes a small
partial peptide of an MRP/cMOAT-related transporter appended
carboxyl-terminal to MRP sequences (MG Belinsky and GD
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Summary Multidrug resistance-associated protein (MRP) and the canalicular multispecific organic anion transporter (cMOAT) are organic
anion pumps that have been linked to cytotoxic drug resistance. We previously reported the isolation of three human MRP/cMOAT-related
transporters, MOAT-B (MRP4), MOAT-C (MRP5) and MOAT-D (MRP3). In the present study we describe the fourth MRP/cMOAT-related
transporter. We analysed ARA, a human cDNA reported to encode a 453 residue MRP-related transporter, and found that it represents a
fused transcript composed of MRP sequences and partial sequences of a novel transporter. The complete coding sequence of this novel
transporter, which we designated MOAT-E, was isolated. MOAT-E encodes a 1503 residue transporter that is most closely related to MRP
(45%), MOAT-D (44%) and cMOAT (39%), both in terms of amino acid identity and sharing a common topology in which ~ 17 transmembrane
spanning helices are distributed within three membrane spanning domains. RNA blot analysis indicated that MOAT-E expression is restricted
to kidney and liver. These observations suggest that MOAT-E may function as an organic anion transporter involved in cellular detoxification
and possibly in the hepatobiliary and renal excretion of xenobiotics and/or endogenous metabolites. Isolation of MOAT-E helps to define the
MRP/cMOAT subfamily of transporters.
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Kruh, unpublished observations). Since ARA, located at 16p13.1
(Kuss et al, 1998), is in close proximity to MRP (16p13.13), and
both of these genes have been reported to be amplified in the drug
resistant cell line from which ARA was isolated (Longhurst et al,
1996), it is possible that the ARA cDNA is the product of a
rearrangement associated with the MRP amplicon. The detection
of cytogenetic abnormalities at 16p in the cell line from which
ARA was isolated is consistent with this possibility (O’Neill et al,
1998). Together these observations suggest that ARA encodes a
partial peptide of a larger transporter whose full-length cDNA has
not yet been described. In the present study we isolate the full-
length cDNA of this novel transporter, which we designated
MOAT-E. We demonstrate that MOAT-E encodes a 1503 residue
ABC transporter that is highly related to MRP, MOAT-D and
cMOAT and whose expression is restricted to kidney and liver.
MATERIALS AND METHODS
Isolation of MOAT-E cDNA
Total RNA prepared from human kidney tissue (a gift of Dr D
Dexter, Hershey Medical Center) was used to prepare cDNA
using the Superscript preamplification system (GibcoBRL,
Gaithersberg, MD, USA) according to the manufacturer’s instruc-
tions. Aliquots of this cDNA were used as template to generate
three overlapping PCR fragments, using oligonucleotide
primers 5¢GGGGCGGCCGCACCATGGCCGCGCCTGCT-
GAGC3¢ (forward) and 5¢GTCTACGACACCAGGGTCAAC3¢
(reverse); 5¢CTGCCTGGAAGAAGTTGACC3¢ (forward) and
5¢CTGGAATGTCCACGTCAACC3¢ (reverse); 5¢GGAGACA-
GACACGGTTGACG3¢ (forward) and 5¢GCCTCGAGT-
CAGACCAGGCCTGACTCC3¢ (reverse). The first three
oligonucleotide primers were designed based upon the predicted
exons of a human genomic clone (GenBank accession number
U91318), and the last three oligonucleotide primers were based
upon the reported sequence of ARA (Longhurst et al, 1996). PCR
products were inserted into pBluescript SK- (Stratagene, La Jolla,
CA, USA) using the restriction sites located at the 5¢ ends of the
first and last oligonucleotide primers, and natural restriction sites
located within the MOAT-E cDNA. Nucleotide sequence analysis
was performed using an ABI 377 DNA sequencer, and the
resulting sequences were assembled using the Sequencher
program (Gene Codes Corporation, Ann Arbor, MI, USA). Protein
sequence analysis was performed using the Wisconsin Package
Version 9.1 (Genetics Computer Group, Madison, WI, USA).
RNA blot analysis
Blots containing poly A+ RNA isolated from human tissues were
purchased from Clontech (Palo Alto, CA, USA) and hybridized
according to the manufacturer’s directions. The 5¢ MOAT-E probe
encompassed nucleotides 342–656 (amino acids 114–219) and the
3¢ MOAT-E probe encompassed nucleotides 3559–4341 (amino
acids 1187–1447) of the cDNA.
RESULTS
Isolation of MOAT-E cDNA
We analysed the sequence of ARA (Longhurst et al, 1996), a cDNA
isolated from a drug-resistant cell line, and found that it is a fused
transcript in which 161 nucleotides of MRP sequence are fused
to 1775 nucleotides of downstream sequences encoding an
MRP/cMOAT-related transporter. The predicted peptide encoded
by the downstream sequences was 438 amino acids (residues
Table 1 Amino acid identity among MRP/cMOAT sub-family membersa
MOAT-E MOAT-B MOAT-C MOAT-D MRP cMOAT
percent identityb
MOAT-E – 33.9 30.6 43.7 45.2 38.9
– (52.0/56.6) (50.0/52.5) (59.3/59.4) (61.3/61.9) (55.3/59.4)
MOAT-B 33.9 – 36.5 35.3 39.4 36.8
(52.0/56.6) – (49.3/59.1) (55.3/54.1) (57.3/61.6) (53.3/55.3)
MOAT-C 30.6 36.5 – 33.1 35.8 36.2
(50.0/52.5) (49.3/59.1) – (57.3/56.9) (60.0/59.4) (61.3/60.6)
MOAT-D 43.7 35.3 33.1 – 57.6 46.8
(59.3/59.4) (55.3/54.1) (57.3/56.9) – (70.7/73.8) (67.3/70.0)
MRP 45.2 39.4 35.8 57.6 – 48.4
(61.3/61.9) (57.3/61.6) (60.0/59.4) (70.7/73.8) – (66.0/73.1)
cMOAT 38.9 36.8 36.2 46.8 48.4 –
(55.3/59.4) (53.3/55.3) (61.3/60.6) (67.3/70.0) (66.0/73.1) –
aOverall percent amino acid identity is indicated in bold-face. Percent identity of nucleotide binding folds 1 and 2 is indicated in parentheses (NBF1/NBF2).
bPercent identity was obtained using the GAP command in the GCG package.
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Figure 1 Schematic comparison of ARA and MOAT-E. The black box
indicates MRP nucleotide sequences located at the 5¢ end of ARA, and the
striped areas denote nucleotide binding folds. The numbering indicates
amino acid residues. ARA residues 1–15 are derived from MRP sequence.
ARA residues 16–453 (accession number X95715) are nearly identical to
MOAT-E carboxyl-terminal residues 999–1503, except as described in the
Results section1344 MG Belinsky and GD Kruh
British Journal of Cancer (1999) 80(9), 1342–1349 © 1999 Cancer Research Campaign 
16–453), less than one-third the size of other MRP/cMOAT
subfamily transporters. A schematic of the predicted fusion protein
encoded by the ARA cDNA is shown in Figure 1. These observa-
tions suggested that the predicted ARA coding sequence did not
represent a protein expressed in normal cells, and that the complete
coding sequence of a novel MRP/cMOAT-related transporter
remained to be isolated. Consistent with this possibility, database
analysis revealed a genomic clone (GenBank accession number
Figure 2 Predicted structure of MOAT-E. Overbars indicate potential transmembrane helices and horizontal arrows indicate the amino-terminal (NBF1) and
carboxyl-terminal (NBF2) nucleotide binding folds. The bullet indicates the position of a potential N-glycosylation site conserved with human MRPIsolation of MOAT-E 1345
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U91318), the predicted exons of which encoded a large potential
protein whose carboxyl-terminus was nearly identical to the 438
residue predicted peptide of ARA. To isolate the full-length coding
sequence of the peptide encoded by the ARA downstream
sequences, we used a reverse transcriptase polymerase chain reac-
tion (RT-PCR) approach in which cDNA prepared from human
kidney RNA served as template for oligonucleotide primers that
were designed based upon genomic clone U91318 and the reported
ARA sequence. This approach yielded a total of ~ 4.5 kb of over-
lapping cDNA clones. Nucleotide sequence analysis revealed an
open reading frame of 1503 residues, the predicted protein of which
we designated MOAT-E.
Figure 3 Comparison of nucleotide binding folds and hydropathy profiles of
MOAT-E with those of related ABC transporters. (A) Comparison of
nucleotide binding folds. The alignment was produced using the PILEUP
command (gap weight 3.0, length weight 0.1) in the Genetics Computer
Group Package version 9.1. Amino acid positions conserved in at least four
of the nine proteins are shaded. In instances where two different amino acids
are each conserved in four proteins both of the residues are shaded. Periods
indicate gaps in the alignment. Walker A and B motifs, and the ABC
transporter family signature sequence C, are indicated by underbars.
Accession numbers are indicated in the legend to Figure 5. (B) Comparison
of hydropathy profiles. Gaps were introduced at the amino-termini of some
proteins to bring the amino-terminal nucleotide binding folds into register.
Nucleotide binding folds are indicated by horizontal bars. Values above and
below the horizontal lines indicate hydrophobic and hydrophilic regions,
respectively. Plots were generated using the Kyte–Doolittle algorithm with a
window of seven residues
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Analysis of the MOAT-E predicted protein
The predicted amino acid sequence of MOAT-E is shown in Figure
2. Typical features of ABC transporters are present in MOAT-E.
Overall, the protein is composed of hydrophobic membrane span-
ning domains and two nucleotide binding folds (NBFs). Conserved
Walker A and B ATP binding motifs, and a conserved C motif,
the signature sequence of ABC transporters, are present in the
NBFs. As shown schematically in Figure 1, the carboxyl-terminus
of the MOAT-E predicted protein (residues 999–1503) corresponds
to the MRP-related peptide encoded by ARA (residues 16–453).
However, the respective amino acid sequences are not completely
identical (96%). Compared to MOAT-E, ARA harbours a small
deletion and four amino acid substitutions. MOAT-E residues
1080–1168 are absent in ARA, and MOAT-E residues A-1215, L-
1287, L-1335 and S-1386, are represented in ARA by threonine,
phenylalanine, valine and cysteine residues respectively.
NBFs are conserved features of ABC transporters, and the
degree of similarity between the NBFs of family members indi-
cates the potential for functional conservation (Higgins, 1992).
Comparison of the NBFs of MOAT-E with other human ABC
transporters indicated that they were most closely related to MRP,
cMOAT and three MRP/cMOAT-related transporters we recently
described, MOAT-B, MOAT-C and MOAT-D (Table 1) (Belinsky
et al, 1998; Lee et al, 1998). Among these transporters, the NBFs
of MOAT-E (NBF1/NBF2) shared the highest degree of identity
with those of MRP (61/62%), MOAT-D (59/59%) and cMOAT
(55/59%). A comparison of the amino acid sequences of the
MOAT-E NBFs with those of related transporters is shown in
Figure 3A. A distinguishing feature highlighted by these align-
ments is the presence of small insertions in the NBF1 of SUR and
MDR1 that are absent in the NBF1 of MOAT-E, other MRP/
cMOAT subfamily members, and CFTR. Consistent with the
analysis of NBFs, overall the MOAT-E predicted protein shared
the highest degree of amino acid identity with MRP (45%),
MOAT-D (44%) and cMOAT (39%) (Table 1). MOAT-E was less
well related to MOAT-B and MOAT-C, with which it shared 34%
and 31% identity respectively.
A comparison of the hydropathy profiles of MOAT-D with other
MRP/cMOAT subfamily transporters, and P-gp, is shown in
Figure 3B. Similar to MRP, MOAT-D and cMOAT, MOAT-E has
three membrane spanning domains, including an amino-terminal
membrane spanning domain that is not present in MOAT-B,
MOAT-C or most other ABC transporters, such as P-gp. A
5 + 6 + 6 configuration of transmembrane spanning helices has
been proposed for MRP and cMOAT, in which the amino-terminal
membrane spanning domain harbours five transmembrane span-
ning helices, and six transmembrane helices are located in both the
second and third membrane spanning domains (Bakos et al, 1996;
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Figure 4 Tissue distribution of MOAT-E transcript. Membranes containing poly-A+ RNA prepared from various human tissues were hybridized with a probe
derived from the 5¢ end of the MOAT-E cDNA (top panel). The same membranes were also hybridized with a control actin probe (middle panel). The bottom
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Hipfner et al, 1997; Kast and Gros, 1997; Tusnady et al, 1997).
The structure of MOAT-D is consistent with this (Belinsky et al,
1998). A combination of computer-assisted analysis using the
TMAP program (Persson and Argos, 1994) and inspection of an
alignment of MOAT-E with MRP, indicated that a 5 + 6 + 6 config-
uration of transmembrane helices is possible for MOAT-E. This
configuration of transmembrane spanning helices is shown in
Figure 2. Using computer-assisted analysis alone another
configuration of transmembrane spanning helices was predicted
(5 + 6 + 4). MRP has been reported to have two N-linked glycosy-
lation sites in its amino-terminus, and another site located between
the first and second transmembrane spanning helix of its third
membrane spanning domain (Hipfner et al, 1997). A potential
amino-terminal N-glycosylation site was conserved in MOAT-E
(Asn-15).
Expression pattern of MOAT-E
ARA was reported to be expressed as a 2.2 kb transcript in the
anthracycline resistant cell line from which it was isolated
(Longhurst et al, 1996). However, an RNA blot of normal human
tissues using ARA sequences as a probe has not been reported. If
MOAT-E represents the normal transcript of ARA, we hypothe-
sized that it should be expressed as a larger sized transcript. To test
this hypothesis, and gain insight into the possible function of
MOAT-E, its expression pattern in a variety of human tissues
was examined. Figure 4 (upper panel) shows an RNA blot using a
MOAT-E probe derived from 5¢ sequences of the cDNA that are
not present in ARA. As expected, a MOAT-E transcript (~ 6 kb)
that is considerably larger than the reported ARA transcript was
detected. In addition, MOAT-E expression was strikingly
restricted. Of the 16 tissues analysed, MOAT-E transcript was
detected only in liver and kidney. This expression pattern suggests
that MOAT-E subserves a specialized function in these two excre-
tory tissues. To confirm that an identical 6 kb transcript was
detected using a probe derived from sequences present in ARA,
another set of membranes containing RNAs prepared from human
tissues was hybridized with a 3¢ MOAT-E probe. As shown in
Figure 4 (lower panel) this probe also detected 6 kb transcripts in
liver and kidney (some degradation is evident in the liver sample).
MOAT-E helps to define the MRP/cMOAT evolutionary
cluster
A cluster analysis of eukaryotic ABC transporters generated using
the PILEUP program of the GCG group package is shown in
Figure 5. This analysis indicates that the known eukaryotic ABC
transporters fall into five families. The MRP/cMOAT subfamily
transporters (MRP, cMOAT, MOAT-B, MOAT-C, MOAT-D and
MOAT-E) reside within a single cluster, which currently contains
the largest number of human ABC transporters. The close relation-
ship between MRP, cMOAT, MOAT-D and MOAT-E is reflected in
the close grouping of these four transporters within the cluster.
Also within the MRP/cMOAT cluster are the yeast transporters
YCF1 and YOR1, and the leishmania transporter PGPA. Like
MRP and cMOAT, these three proteins have been reported to
transport organic anions (Ouellette et al, 1990; Gui et al, 1996; Li
et al, 1996). However, two proteins that are not known to function
as organic anion transporters also reside within this cluster. The
cystic fibrosis transmembrane conductance regulator, CFTR, func-
tions as an ATP-regulated chloride channel, and the sulphonyl urea
receptor, SUR, functions to regulate potassium channels.
DISCUSSION
We previously reported the complete coding sequences of MOAT-B
(MRP4), MOAT-C (MRP5) and MOAT-D (MRP3), three MRP/
cMOAT subfamily members (Belinsky et al, 1998; Lee et al, 1998).
Based upon the degree of amino acid identity and overall protein
topology, we found that the MRP/cMOAT subfamily could be
divided into two groups. The first group was composed of MRP,
cMOAT and MOAT-D, three transporters that share a high degree of
amino acid identity (47–57%), and a common topology character-
ized by a third membrane spanning domain located at their amino-
termini. In contrast, MOAT-B and MOAT-C were somewhat less
well-related to MRP (39% and 36% respectively) and did not have
amino-terminal hydrophobic extensions. The isolation of MOAT-E
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Figure 5 Cluster analysis of selected eukaryotic ABC transporters. The
alignment was generated using the PILEUP command in the GCG package.
Accession numbers are as follows: Hum/ABCR: AF000148; Mus/ABC1:
X75926; Mus/ABC2: X75927; Hum/ABCC: X97187; Hum/ALDP: P33897;
Hum/ALDR: AJ000327; Hum/PMP70: P28288; Hum/MDR1: P08183;
Hum/MDR3: M23234; Hum/TAP1: Q03518; Hum/TAP2: 106985; Ysc/STE6:
M26376; Spo/HMT1: Q02592; Hum/MRP: P33527; Hum/cMOAT: U63970;
Hum/MOATB: AF071202; Ysc/YCF1: P39109; Hum/SUR: Q09428;
Ysc/YOR1: P53049; Lei/PGPA: P21441; Hum/CFTR: P13569; Can/CDR1:
P43071; Ysc/PDR5: L19922; Spo/BFR1: D55697; Ysc/SNQ2: P32568;
Dro/SCRT: U39739; Hum/WHIT: P45844; Dro/BROW: P124281348 MG Belinsky and GD Kruh
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now extends the number of full-length MRP/cMOAT-related trans-
porters to four, and helps to further define this subfamily. Of the
known MRP/cMOAT subfamily members, MOAT-E is most closely
related to MRP (45%), MOAT-D (44%) and cMOAT (39%). In
addition, similar to topological models proposed for the latter three
protein, analysis of the primary structure of MOAT-E suggests a
model in which 17 transmembrane spanning helices are distributed
within three membrane spanning domains in a 5 + 6 + 6 configura-
tion. Thus, MOAT-E belongs to the first group of MRP/cMOAT-
transporters we described. Two recently reported transporters
isolated from rat liver, MLP-1 and MLP-2 (Hirohashi et al, 1998),
are orthologues of MOAT-E (81.5% identity) and MOAT-D (79.6%
identity), respectively.
Based upon the close relationship of MOAT-E to MRP and
cMOAT, we speculate that it may also function as an organic anion
transporter. MRP has been reported to transport a variety of
amphiphilic conjugates, including several glutathione S-conjugates,
such as the endogenous substrates LTC4 and oxidized glutathione,
and xenobiotic conjugates such as DNP-glutathione and monoglu-
tathionyl melphalan (Leier et al, 1994, 1996; Muller et al, 1994). In
addition, several sulphated and glucuronidated compounds are MRP
substrates (Jedlitschky et al, 1996; Loe et al, 1996). In the case of
cMOAT, genetic and biochemical studies of rat strains that are defi-
cient in this protein originally indicated that it functions as an impor-
tant transporter of amphipathic conjugates into bile (Jansen et al,
1985; Mikami et al, 1986). More recently, several studies using the
cloned cMOAT cDNA have confirmed this substrate specificity.
Transient expression of rat cMOAT in COS cells and Xenopus laevis
oocytes has been reported to induce increased cellular efflux of 2,4-
dinitrophenyl-S-glutathione and LTC4 (Madon et al, 1997). In addi-
tion, enhanced ATP-dependent uptake of glutathione S-conjugates
by cMOAT-enriched membrane vesicles prepared from insect cells
(Remon et al, 1998) and stably transfected cells (Madon et al, 1997;
Evers et al, 1998; Ito et al, 1998) has been reported. Studies using
the MOAT-E cDNA should determine whether it shares the substrate
specificity of MRP and cMOAT, or possibly transports a distinct
class of compounds.
Using RNA blot analysis, we found that MOAT-E transcript was
abundant in liver and kidney, but undetectable in many other human
tissues. This expression pattern is distinct from those of other
MRP/cMOAT subfamily transporters. MRP and MOAT-C are
widely expressed, cMOAT is expressed at high levels in the liver,
and low levels in small intestine and kidney, MOAT-B is highly
expressed in prostate, but also expressed in other tissues, and
MOAT-D is expressed in colon, pancreas, liver and kidney, with
lower levels in small intestine, prostate and placenta (Kruh et al,
1995; Buchler et al, 1996; Paulusma et al, 1996; Kool et al, 1997;
Suzuki et al, 1997; Schaub et al, 1997; Belinsky et al, 1998; Lee et
al, 1998). The MOAT-E expression pattern suggests that it may
participate in hepatobiliary and renal excretion of organic anions.
While cMOAT is a major pump for organic anions in liver, the hepa-
tobiliary excretion of organic anions is not completely abolished in
cMOAT-deficient rat strains, suggesting the existence of other
organic anion transporters. MRP is expressed in hepatocytes, but its
level is low, and it is localized at the lateral membrane which does
not communicate with bile canaliculi (Mayer et al, 1995). MOAT-E
may therefore function as an alternative system to cMOAT for the
hepatobiliary excretion of organic anions. It is also possible,
however, that MOAT-E subserves a different function in the liver.
The abundant expression of MOAT-E transcript in kidney is particu-
larly interesting. While cMOAT is expressed in the kidney, its
expression level is low, and the urinary excretion of organic anions
has been reported to be largely unaffected in cMOAT-deficient TR-
rats (Huber et al, 1987; de Vries et al, 1989). Thus MOAT-E may
function as an ATP-dependent transporter of organic anions into
urine. The excretion of organic anions into urine is particularly rele-
vant to methotrexate. A role for cMOAT in the hepatobiliary excre-
tion of this agent has been proposed based upon the observation that
cMOAT-deficient mice have increased plasma levels, and decreased
biliary excretion of this agent (Masuda et al, 1997). However, in
humans methotrexate is predominately excreted into the urine
(Allegra and Grem, 1997). MOAT-E is therefore a potential candi-
date for the renal transporter involved in the urinary excretion of this
agent. MOAT-D is also well-expressed in kidney (Belinsky et al,
1998) and may therefore also play a role in organic anion excretion
by the kidney. Additional studies should determine whether MOAT-
E is involved in the renal and hepatobiliary excretion of organic
anions, and whether it plays a role in the cellular detoxification of
natural product cytotoxic drugs.
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Two other groups have recently reported the complete MOAT-
D/MRP3 coding sequence: Kiuchi et al (1998) FEBS Lett 433:
149–152 and Uchiumi et al (1998) Biochem Biophys Res Commun
252: 103–110. Following submission of our manuscript, the MRP6
coding sequence was reported by Kool et al (1999) Cancer Res 59:
175–182. The MRP6 coding sequence is identical to the MOAT-E
sequence with the exception of two amino acid residues.
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